Dr Jan Král (Institute for Clinical and Experimental Medicine, Czech Republic) and colleagues investigated the differences in IBD care and education across Europe [1]. An online survey examining IBD education, IBD clinical care, and demographics was distributed across 39 European countries. In total, 1,268 participants responded. Results were compared between high- and low-income countries, based on GDP per capita.
Physicians from high-income countries reported a better access to IBD-specific training than their colleagues from low-income countries (56.4% vs 38.5% positive responses, respectively; P<0.001). Nonetheless, most physicians feel comfortable in treating IBD patients (77.2% vs 72.0%; P=0.04). More dedicated IBD units are available in high-income countries (58.5% vs 39.7%; P<0.001), and physicians in high-income countries organise more multidisciplinary meetings. In the current era, physicians in high-income countries are more inclined to make use of telemedicine. Furthermore, physicians in high-income countries have a better access to most IBD medications, especially biologics.
- Král J, et al. Large differences in IBD care and education across Europe, first results of the pan-European VIPER study. DOP37, ECCO 2021 Virtual Congress, 2-3 & 8-10 July.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Ultra-processed food intake associated with IBD Next Article
Risk of colorectal cancer is detected by low-pass whole genome sequencing »
« Ultra-processed food intake associated with IBD Next Article
Risk of colorectal cancer is detected by low-pass whole genome sequencing »
Table of Contents: ECCO 2021
Featured articles
Biologics Updates
Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD
Ustekinumab safe and effective in elderly CD patients
Early clinical remission and response following risankizumab therapy in CD
Risk of hospitalisation and surgery linked to IBD biological
Obesity increases the risk of immunogenicity to adalimumab in IBD
Improvements in Small Molecules
Upadacitinib meets primary endpoint for moderate-to-severe UC
Promising safety and pharmacokinetic data on BT051 for UC
Surgical closure plus anti-TNF outperforms anti-TNF alone for perianal fistula
Novel Biomarkers
Blood proteins predicting relapse in CD identified
Extracellular RNA has potential as a non-invasive biomarker in IBD
Risk Mitigation
No increased risk of (severe) COVID-19 among IBD patients
Oral faecal microbiota transplant therapy efficacious in UC
Artificial intelligence outperforms human classifying of endoscopic images in UC
Increased risk of rectal cancer after colectomy in IBD
Risk of colorectal cancer is detected by low-pass whole genome sequencing
Large variability in IBD care and education across Europe
Ultra-processed food intake associated with IBD
Factors of coping difficulties in IBD revealed
Related Articles
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/12/podcast-icoon-1.jpg)
October 13, 2022
UEGW 2022 Highlights Podcast
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com